[Clinical value of "zero-hour biopsy"]

Magy Seb. 2009 Aug;62(4):188-98. doi: 10.1556/MaSeb.62.2009.4.3.
[Article in Hungarian]

Abstract

In spite of the improving results the long-term benefits of renal transplantation fell behind the expectable potential possibilities. The main cause of kidney graft loss is chronic allograft nephropathy following cardiovascular deaths. This is such a multiple etiologic clinical picture which may occur at any time. When adequate treatment is not available in time repeated development of chronic renal failure is unavoidable. The aim of my study is, how can we rise the number of transplanted kidney and the quality of them.

Publication types

  • Case Reports
  • English Abstract

MeSH terms

  • Animals
  • Biopsy* / methods
  • Brain Death
  • Cell Survival / drug effects
  • Europe
  • Glomerulosclerosis, Focal Segmental / etiology
  • Glomerulosclerosis, Focal Segmental / prevention & control
  • Graft Survival / drug effects*
  • Humans
  • Hungary
  • Immunosuppressive Agents / administration & dosage
  • Immunosuppressive Agents / adverse effects*
  • Kidney / drug effects
  • Kidney / pathology*
  • Kidney Failure, Chronic / diagnosis
  • Kidney Failure, Chronic / etiology
  • Kidney Failure, Chronic / prevention & control
  • Kidney Transplantation* / standards
  • Male
  • Middle Aged
  • Neuroprotective Agents / therapeutic use
  • Pituitary Adenylate Cyclase-Activating Polypeptide / therapeutic use*
  • Pituitary Adenylate Cyclase-Activating Polypeptide / ultrastructure
  • Program Development
  • Rats
  • Rats, Wistar
  • Renal Insufficiency, Chronic / diagnosis*
  • Renal Insufficiency, Chronic / etiology
  • Renal Insufficiency, Chronic / pathology
  • Renal Insufficiency, Chronic / physiopathology
  • Renal Insufficiency, Chronic / prevention & control*
  • Reperfusion Injury / etiology
  • Reperfusion Injury / prevention & control*
  • Tissue and Organ Harvesting / methods
  • Transplantation, Homologous

Substances

  • Immunosuppressive Agents
  • Neuroprotective Agents
  • Pituitary Adenylate Cyclase-Activating Polypeptide